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Abstract
Introduction. Infections in patients with systemic lupus
erythematosus (SLE) are a significant factor of morbidity
and mortality. Although central nervous system infections,
including septic meningitis, are rare in patients with SLE,
they can be significant causes of mortality inspite of the
prompt and accurate diagnosis and proper management.
Case report. We presented a woman with the diagnosis of
SLE and diffuse proliferative lupus nephritis. Because of
disease activity we introduced cytostatic immunosuppres-
sive therapy, cyclophosphamide and then azathioprine.
Meningoencephalitis, staphylococcal sepsis and abscess of
the brain, with resulting seizures developed. Conclusion.
This case alerts to the need of careful examination of pa-
tients with SLE, collection of adequate cultures and
evaluation of predisposition towards ifnections, before the
introduction of immunosuppressants due to potentially
fatal infection.
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Apstrakt
Uvod. Infekcije kod bolesnika sa sistemskim eritemskim
lupusom (SEL) znaÿajan su faktor morbiditeta i mortalite-
ta. Mada su infekcije centralnog nervnog sistema ukljuÿu-
juýi septiÿni meningitis, retke kod bolesnika sa SEL, one
mogu biti znaÿajan uzrok mortaliteta i pored brze dijagno-
ze i adekvatne terapije. Prikaz bolesnika. Prikazali smo
bolesnicu sa SEL kod koje je došlo do razvoja meningoen-
cefalitisa i apscesa mozga pri pokušaju uvoĀenja citostat-
ske imunosupresivne terapije ciklofosfamidom, a potom
azatioprinom. Kao posledica apscesa ostala je encefalo-
malacija temporoparijetalnog dela mozga sa poslediÿnim
epi napadima. Zakljuÿak. Ovaj sluÿaj ukazuje na potrebu
pažljivog pregleda svakog bolesnika sa SEL, kao i procene
sklonosti prema infekcijama pre uvoĀenja terapije drugim
imunosupresivnim agensima (pored glikokortikosteroida),
zbog potencijalno fatalnih infekcija koje se kod njih mogu
razviti.
Kljuÿne reÿi:
lupus, eritematozni, sistemski; nervni sistem, centralni,
infekcije; meningoencefalitis; imunosupresija.
Introduction
It is known that viral and bacterial infections may be
the trigger of development or exacerbation of systemic lupus
erythematosus (SLE). The patients with SLE are more prone
to infections either due to the nature of disease or the applied
immunosuppressive therapy 
1. About 80% of infections in
SLE patients are caused by bacteria. Common acute infec-
tions in these patients are: pneumonia, urinary infections,
cellulitis and sepsis 
2. Of chronic infections, the most fre-
quent is tuberculosis 
3, while fungal infections, and those
caused by parasites and protozoa are most often opportunis-
tic infections 
4–6.
Central nervous system (CNS) infections, including septic
meningitis, are rare bacterial complications in SLE, but they
can be significant cause of mortality 
7. These infections are
most commonly the consequence of a long-term immunosup-
pressive therapy, and can be a diagnostic problem by mimick-
ing activity of lupus and neurolupus. We presented the  instruc-
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Case report
A 33-year-old female patient, has been treated for SLE
since 2004. The onset of disease was sudden in March 2004,
with edemas, pains and stiffness of joints and febrile condi-
tion which was followed by cervical and axillary lymphade-
nopathy, hepatosplenomegaly and anemia (hematological
disease was ruled out on the basis of bone marrow puncture).
On admission, bilateral neck and axillary lymph nodes were
enlarged, the patient had hepatosplenomegaly. We observed
an abscess on the left gluteus.
Laboratory results showed elevated erythrocyte sedi-
mentation rate (ESR 80) and leukocytosis (11.4 u 10
9/L),
anemia >hemoglobin (Hb) 97 g/L@ and slight thrombocytope-
nia (131 u 10
9/L). Biochemistry was normal (with hypoal-
buminemia of 28 g/L). Immunological analyses showed high
immunoglobulin G (21.9 g/L), consumption of complements
(C3 = 0.43 g/L and C4 < 0.04 g/L), positive antinuclear anti-
bodies (ANA) homogenous 1 : 640, ds DNA ++++, positive
anticardiolipin antibodies (ACLA) and positive Coombs test.
The urine sediment showed 8–10 fresh, 10–12 pale erythro-
cytes. Urine culture was negative, 24-hour proteinuria bellow
0.5 g. Gluteal wound swab: Escherichia coli X-ray of the
heart and lungs and heart ultrasonography showed minor
pericardiac effusion.
The patient was diagnosed with SLE on the basis of
American College of Rheumatology (ACR) criteria: polyar-
thralgia, cytopenia, positive ANA, ds DNA, ACLA, pericar-
ditis, and erythrocyturia. The therapy included parenteral
glucocorticosteroids (GCS), followed by oral prednisone of 1
mg/kg body weight (bw) in decreasing doses, antibiotics, an-
tiaggregation therapy, H2 blockers. Later, after improving,
the patient was on maintenance prednisone dose of 30 mg.
In November 2004, the patient developed  the signs of
iatrogenic Cushing’s syndrome. Due to increase in protein-
uria (up to 3.5 g/24 h) and massive erythrocyturia, kidney bi-
opsy was performed and revealed diffuse-proliferative glo-
merulonephritis with activity and chronicity indexes of 4/24
and 3/12, respectively.
Further treatment included two-time pulse therapy with
the intravenous (iv) methylprednisolone, 500 mg, followed
by pulse therapy of iv cyclophosphamide, 800 mg. The pa-
tients was advised to take prednisone 20 mg, azathioprine 50
mg, and drugs for gastric mucosal protection.
Eighteen days after iv cyclophosphamide pulse therapy,
the patient developed massive left-side effusion, hypertension,
lower leg edemas, hepatosplenomegaly. During the same eve-
ning, the patient’s condition worsened, she was febrile (38
oC)
with a headache. We evacuated 1,400 mL of serous pleural
exudation. Proteinuria was 9.39 g/24 h. Parenteral quinolones
and cephalosporins were empiricaly introduced in full doses,
as well as iv methylprednisolone, 3 u 40 mg.
Neurological findings revealed positive meningeal signs
without lateralization. Lumbal puncture was performed, and
the cerebrospinal fluid was turbid, pouring out under intense
pressure. The analysis revealed cerebrospinal fluid (CSF)
with 820 cellular elements (98% neutrophils, 2% lympho-
cytes), hypoglycorrhachia, 1.94 mmol/L, and hyperproteinor-
rhachia, 1.78 g/L. Etiological examinations of CSF were
negative.
The patient was transferred to the Clinic of Infectious
Diseases.
Antimicrobial therapy was continued by: ampicilin 3 u
3.0 g iv, gentamicin 120 mg, rifampicin 600 mg. After 6
days, isoniazid 300 mg and pirazinamide 1,500 mg were
added, because specific CNS infection was suspected. Al-
though antimicrobial and antiedematous therapy was contin-
ued, her condition became aggravated, manifested by gener-
alized epileptic seizures. The introduction of antiepileptics
(phenobarbiton and carbamazepine) made convulsions stop.
Endocranial computed tomography (CT) was carried out and
the right temporoparietal hypodense area was evident. At
that time, ampicilin was ruled out and vancomycin, 3 u 500
mg, was introduced (in condition of sufficient diuresis), be-
cause of cerebritis.  Few days later, endocranial magnetic
resonance imaging (MRI) demonstrated meningoencephalitis
of the right temporo-basic region together with encephalo-
malacia (Figure 1) and Staphylococcus aureus was isolated
Fig. 1 – Endocranial magnetic resonance imaging meningoencephalitis of the right
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from two blood cultures.  At that time, middle-grade renal
failure was registered (creatinine clearance  27.6 mL/min).
According to therapeutic algorithm, we introduced mero-
penem (but in doses of 3 u 1.0 g) with fluconasol. After few
days, antituberculotic therapy was excluded. Three weeks
later, when the patient's clinical improvement was evident
and renal function was repaired (proteinuria 0.89 g/24 h),
vancomycin and meropenem were ruled out and antimicro-
bial therapy was continued with gentamicin 120 mg and ce-
fotaxim  2 u 3.0 g.
Anemia was corrected by the substitution therapy.
Control endocranial MRI showed a significant regression of
above-described pathological changes but, in further course,
agranulocytosis was noted and bone marrow puncture was
done. Filgrastim, a colony- stimulating factor, was added, re-
sulting in the retrieval of white blood cell count and afebrile
condition. In the meantime, the patient experienced abdomi-
nal difficulties, with clinical and radiologic picture of ileus
and underwent surgical interventions (laparotomy, ascites
evacuation and drainage). Postoperative course was unevent-
ful. Further on, the patient was better, proteinuria was about
1 g/daily. A gluteal abscess developed again, in the right re-
gion, and was treated (Figure 2).
In June 2005, worsening of urine sediment and protein-
uria occurred, so we introduced mycophenolate-mofetil in
increasing doses to 2 g/day. After several days, the patient
developed fever and acute bronchitis, followed by nausea,
and laboratory inflammatory syndrome. Because of that, my-
cophenolate therapy was discontinued.
In further course there has been no attempt to introduce
immunosuppressive therapy other than GCS. Control endo-
cranial MRI (Figure 3), showed right temporoparietal hypo-
dense area. During the last hospital stay in October 2011, the
patient felt mostly well, with occasional events of bronchitis,
rare epileptic seizures (approximately 1 per month) and
without significant proteinuria.
Fig. 2 – An abscess in the right gluteal region.
Fig. 3 – Control endocranial magnetic resonance imaging findings: right temporoparietal hypodense area;
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Discussion
One of the most severe complications during SLE con-
dition may be CNS infection, which is most commonly the
consequence of a long-term use of GCS and other immuno-
suppressive agents, as well as immune disorder due to the
illness itself. The majority who died from infection were on
high dose prednisolone plus at least 1 other immunosuppres-
sive agent and had serologically active disease 
8. CNS infec-
tion symptoms may mimic the activity of the disease or,
conversely, may be camouflaged by GCS therapy 
9.
Reviewing the causes/focus of CNS infection, the pos-
sibilities in the presented case were multiple: predisposition
to infections due to conditions with complement deficit and
reduced bacterial clearance via reticuloendothelial system;
higher exposure to respiratory infections within her envi-
ronment (pre-school and school children at home, poor eco-
nomic conditions); the existing chronic sinusitis (CT-viewed
opacification of paranasal cavities) with the possibility of in-
fection spread and the presence of “silent foci” (such as glu-
teal abscess) which became reactivated upon immunosup-
pression and could reached the CNS through circulation. In
addition, the risk factors of infections described in the lit-
erature 
10–14 such as: nephritis, activity of the disease, leuko-
penia, positive dsDNA > 20 IU/mL,  prednison in daily dose
higher than 10 mg, application of cyclophosphamide, to-
gether with hypocomplementemia presenting the independ-
ent predictive factor, were all found in our patient.
Due to GCS side effects and the activity of the disease,
the presented patient received iv pulse cyclophosphamide
therapy followed by oral azathioprine 
15, which produced
many side effects, among them life-threathening  CNS in-
fection.
At that time, the question of differential diagnosis was
raised: whether it was about SLE exacerbation and develop-
ment of neurolupus, or even manifestation of antiphospho-
lipid syndrome (APLS), or CNS infection. The following ex-
aminations were performed: lumbal puncture, CT scanning
and MRI imaging, which confirmed the infection of CNS
and ruled out CNS vasculitis and APLS (ACA were, except
for the first result, several times negative). We concluded
that it was the case of acute neuroinfection in the immuno-
suppressed patient.
Clinical picture and course of disease with positive
blood culture results indicated Staphylococcus aureus infec-
tion. This is supported by the fact that epileptic seizures first
occurred during meningoencephalitis and occasionally kept
on appearing as the consequence of encephalomalacia.
The patient's condition demanded antibiotic therapy
from the beginning. After neuroradiologic diagnostics and
positive blood culture, anticerebritic therapy was necessary:
combination of the third generation cephalosporines with
vancomycin, and consenquently, the combination of mero-
penem and vancomycin were used 
16, 17. From the beginning,
the patient was on full-dose antibiotic therapy. At the mo-
ment of decission about meropenem dosage, we were guided
by the two facts: the patient had middle-stage renal failure,
and meningoencephalitis had already achieved clinical im-
provement, so the dose of meropenem was adapted (from the
recommended dose of  3 u 2.0 g to  3 u 1.0 g).
We consider this report instructive and interesting be-
cause of many aspects. CNS infections are rare in patients
with SLE, but they can be significant causes of mortality.
Kim et al. 
7 found 1,420 Korean patients with SLE out of
whom 20 (1.4%) had meningitis.
During a 20-year review period, among 3,165 Taiwan-
ese SLE patients, Hung et al. 
18 identified 17 patients with
CNS infections. Cryptoccocus neoformans was the causative
microorganism in 10 patients and bacterial meningitis was
found in 7 of then. Most patients (94%) had active SLE at
the time of CNS infection. A total of 15 patients received
corticosteroid therapy, and of these, 7 in combination with
immunosuppressive agents. The mortality rate was extremely
high (41.2%) 
18. The presented patient also had active SLE at
the time of infection, and received GCS therapy in conjunc-
tion with immunosuppressive agents.
Yang et al. 
19 described 38 SLE patients with CNS in-
fections (Mycobacterium tuberculosis was identified in 19 of
the patients, Listeria monocytogenes in 3, Klebsiella pneu-
moniae in 1, Staphylococcus aureus in 1, Cryptococcus
neoformans in 12 patients, and Aspergillus fumigatus in 1
patient).
In 2009, Baizabal-Carvallo et al. 
20 reported 23 patients
with SLE and meningitis among 1,411 SLE patients in
Mexico.
Conclusion
Since SLE patients are at higher risk of infections, be-
fore utilization of any immunosuppressive therapy, it is nec-
essary to identify infections. Complete and careful examina-
tion of a patient, collection of throat, nasal and sputum
swabs, urine culture as well as monitoring of CNS manifes-
tations are required for choosing the therapy. Also, care is
required about additional risk factors (mentioned above), and
individial disposibility for infection, and to be aware that in-
fection  in immunosuppressed patients  can be unpredictible.
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